CV manifestations and sequelae of COVID-19
Also called COVID heart, coronavirus cardiovascular, long COVID cardiac
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
COVID-19 is a viral disorder caused by the SARS-CoV-2 VIRUS.1 Cardiovascular diseases are pathological conditions involving the cardiovascular system, including the heart, blood vessels, or pericardium.
The Gam-COVID-Vac vaccine was evaluated in a phase 3 trial at 25 hospitals and polyclinics in Russia.1
Vaccine effectiveness against COVID-19 beyond 6 months remains incompletely understood.1
Independent and Joint Associations of the Planetary Health Diet Index and Triglyceride‐Glucose Index With Mortality and Prevalent Cardiovascular Disease in Adults With Overweight or Obesity: NHANES 2005–2018
The FASEB Journal — Ma C — Nov 2026
“Are you going to get busy living or are you going to get busy dying?” Traumatic stressors in older adult–caregiver dyads during COVID-19 social scarcity in the USA
International Journal of Qualitative Studies on Health and Well-Being — Kilaberia T — Nov 2026
An active national survey of the BNT162b2 mRNA COVID-19 vaccine safety in Israeli children
Human Vaccines & Immunotherapeutics — Zatlawi M — Nov 2026
Detection of SARS‐CoV‐2 in Semen Months After COVID‐19: Potential Evidence of Low‐Level Replicative Persistence
Andrology — Furtado M — Nov 2026
Understanding the Support Needs of People With Long COVID: A Qualitative Study in Aotearoa New Zealand
Health Expectations — McKenzie F — Nov 2026
Pharmacists’ perspectives on efficiencies and other benefits of combination influenza/COVID-19 vaccination
Journal of Medical Economics — Sweeney C — Nov 2026
Real-world safety outcomes of COVID-19 mRNA vaccine: A result from Korea post-marketing surveillance
Human Vaccines & Immunotherapeutics — Han S — Nov 2026
Role of protein lactylation in pulmonary and cardiovascular diseases: Current research and future perspectives (Review)
Molecular Medicine Reports — Pan Z — Nov 2026
Disentangling enforced and voluntary behaviour change during the COVID-19 Pandemic, the Netherlands, 2020 to 2023
Eurosurveillance — Bussemakers C — Nov 2026
Avascular necrosis of the femur following COVID-19: an updated systematic review
Archives of Orthopaedic and Trauma Surgery — Azadvari M — Nov 2026
Sessions from public communities on Synapse. RSVP to join the live discussion.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
The Lancet — Logunov D
1,748 citations · 2021 · among the most cited on COVID-19 cardiovascular
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030
The Lancet — Vogel B
1,586 citations · 2021 · among the most cited on COVID-19 cardiovascular
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
The Lancet — Ridker P
711 citations · 2023 · among the most cited on COVID-19 cardiovascular
Diagnostics for COVID-19: moving from pandemic response to control
The Lancet — Peeling R
487 citations · 2021 · among the most cited on COVID-19 cardiovascular
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
The Lancet — Nordström P
339 citations · 2022 · among the most cited on COVID-19 cardiovascular
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
La Jolla Institute for Immunology
h-index 176 · 123k citations
COMBO ‐ RATE : An Experimentally Validated Bioinformatic Tool to Identify Promiscuous HLA Restrictions
Most-cited researchers publishing on COVID-19 cardiovascular.
